GSK's ICOS Agonist Disappointment Another Setback For Anticancer Ambitions
Feladilimab Phase II Combination Study With Keytruda Halted
GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.
